King's College Hospital

Leading Academic Neurosurgeons Describe New NICO Myriad SPECTRA™ System as a 'Game-Changing Advancement' in Surgical Removal of High-Grade Glioma Brain Tumors

Retrieved on: 
Friday, May 3, 2024
AANS, FDA, University, Medication, Brain, Food, NICO, UAMS, Neuroscience, Health care, Surgeon, Doctor of Philosophy, Medicine, Neurosurgery, Patient, King, MIPS, MHRA, Fluorescence, Neoplasm, Collection, King's College Hospital, Medical imaging

New NICO SPECTRA is only hand-held technology delivering blue light closer to target to enhance tissue fluorescence.

Key Points: 
  • New NICO SPECTRA is only hand-held technology delivering blue light closer to target to enhance tissue fluorescence.
  • "Sending light deep into the brain is not easy and can make these cases extremely difficult.
  • The SPECTRA System provides illumination, resection, collection and biological preservation of tissue for the surgical removal of brain tumors and intracerebral hemorrhages using minimally invasive and open craniotomy surgical approaches.
  • Learn more about NICO technologies at NICOneuro.com ; follow us on LinkedIn and Twitter , view surgical and patient videos on YouTube .

Children’s Hospital Los Angeles Researchers Develop Clinical Tool to Predict if a Child in Acute Liver Failure Will Need a Transplant

Retrieved on: 
Monday, October 23, 2023
Software, Research, Internet, Family, Consumer, Apps, Applications, Technology, Hospitals, Children, Science, Surgery, Health, Liver injury, Child, Children's Hospital Los Angeles, PELD, Smartphone, Liver, MD, USC, Viral hepatitis, Cirrhosis, Doctor of Philosophy, FRCSC, MBBS, Immune-mediated inflammatory diseases, FACS, King's College Hospital NHS Foundation Trust, Division, Chronic liver disease, Risk, National Cancer Institute, CHLA, Nutrition, Probability, King's College Hospital, Hepatotoxicity, Liver failure, NIH, MHA, Hospital, Patient, Transplant, Acute liver failure, Diagnosis, Death, MS, Dietary supplement, Birth control, Gastroenterology

Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.

Key Points: 
  • Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.
  • While pediatric acute liver failure has been linked to both viral hepatitis and drug-induced liver injury, at least half of cases have no apparent trigger.
  • The CHALF Score predicts if a child experiencing acute liver failure will recover or should be referred to a transplant center.
  • Doctors do not want to refer a child for liver transplant who could otherwise recover with medical treatment—about 70% of children with acute liver failure recover while keeping their original liver.

NICO Awards $40,000 Grant to London's Kings College Hospital

Retrieved on: 
Thursday, October 12, 2023
CONNECT, Neoplasm, DRS, Physician, DSM-IV codes, Biomarker, Regeneration, White matter, Research, IIS, Neuro, Neurosurgery, Brain, King, NICO, MD, King's College Hospital, MIPS, Patient, Medical imaging, Neuroscience

INDIANAPOLIS, Oct. 12, 2023 /PRNewswire/ -- Ranjeev Bhangoo, MD, and Jose Lavador, MD, neurosurgeons from Kings College Hospital in London, have received a $40,000 Investigator Initiated Study (IIS) grant from NICO Corporation to assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO's BrainPath and a conventional surgical approach following deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

Key Points: 
  • Dr. Bhangoo is Clinical Director of Neuroscience and Dr. Lavador a Consultant Neurosurgeon at King's College Hospital.
  • They are seeking a better understanding of the impact NICO technologies have on patient recovery.
  • Existing published data suggests that NICO technologies cause less damage to brain fiber tracts when accessing tumors in deep subcortical regions of the brain.
  • The NICO Investigator Initiated Study (IIS) grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

NICO Awards $40,000 Grant to London's Kings College Hospital

Retrieved on: 
Thursday, October 12, 2023
CONNECT, Neoplasm, DRS, Physician, DSM-IV codes, Biomarker, Regeneration, White matter, Research, IIS, Neuro, Neurosurgery, Brain, King, NICO, MD, King's College Hospital, MIPS, Patient, Medical imaging, Neuroscience

INDIANAPOLIS, Oct. 12, 2023 /PRNewswire/ -- Ranjeev Bhangoo, MD, and Jose Lavador, MD, neurosurgeons from Kings College Hospital in London, have received a $40,000 Investigator Initiated Study (IIS) grant from NICO Corporation to assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO's BrainPath and a conventional surgical approach following deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

Key Points: 
  • Dr. Bhangoo is Clinical Director of Neuroscience and Dr. Lavador a Consultant Neurosurgeon at King's College Hospital.
  • They are seeking a better understanding of the impact NICO technologies have on patient recovery.
  • Existing published data suggests that NICO technologies cause less damage to brain fiber tracts when accessing tumors in deep subcortical regions of the brain.
  • The NICO Investigator Initiated Study (IIS) grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer

Retrieved on: 
Thursday, August 3, 2023
Parisa, University, University of London, Therapy, Doctor of Philosophy, Smith-Kettlewell Eye Research Institute, AMD, Pharmacovigilance, Retinitis pigmentosa, Quality of life, Geographic atrophy, Hope, Statistics, GA, CMO, King's College Hospital, Gesellschaft mit beschränkter Haftung, Harvard Medical School, Ophthalmology, Novartis, Massachusetts Eye and Ear, Patient, CTX, Schepen, Ear, Pharmaceutical industry, Medical device

MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.

Key Points: 
  • MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.
  • Dr. Zamiri joins CTx from Graybug Vision, Inc., where she held the position of Chief Medical Officer and was responsible for all clinical, statistics, regulatory and medical affairs activities, successfully completing phase II development of their lead asset for wet age-related macular degeneration.
  • "We are excited to welcome Parisa to the CTx team as CMO," said Dr Rafiq Hasan, Chief Executive Officer.
  • said Dr Parisa Zamiri, Chief Medical Officer.

KLAS Names Oracle Global EMR Market Share Leader for Eighth Straight Year

Retrieved on: 
Monday, June 26, 2023
Bed, Oracle Corporation, EMR, Health, Trust, Cerner, King's College Hospital, KLAS, Hospital, Princess Alexandra, Patient, Oracle Health Sciences, United Kingdom, Health information management, United Arab Emirates, Nursing, Oracle

AUSTIN, Texas, June 26, 2023 /PRNewswire/ -- Oracle Health remains the worldwide leader in electronic health records for the eighth consecutive year, according to the 2023 KLAS Global EMR Market Share report.

Key Points: 
  • AUSTIN, Texas, June 26, 2023 /PRNewswire/ -- Oracle Health remains the worldwide leader in electronic health records for the eighth consecutive year, according to the 2023 KLAS Global EMR Market Share report.
  • In addition to citing Oracle Health's market leadership, the report noted Oracle's strong year in EMR wins with large multihospital systems in Canada, the United Kingdom, the United Arab Emirates, and Germany.
  • "It is clear that the combination of Oracle and Cerner is helping customers succeed, driving innovation, and accelerating our momentum in the market," said Travis Dalton, executive vice president and general manager, Oracle Health.
  • In addition to acknowledging Oracle Health's strong global performance, KLAS also recognized its double-digit hospital growth in its 2023 U.S. Hospital EMR Market Share report.

LiverMultiScan® Detected Earlier Stages of Treatable Disease in Patients With Autoimmune Hepatitis to Allow Tailored Treatment

Retrieved on: 
Tuesday, March 22, 2022
General Health, Medical Devices, Health, Other Technology, Technology, Risk, Autoimmune hepatitis, Diagnosis, King's College Hospital, HIV disease progression rates, Genetics, Oxford University Hospitals NHS Foundation Trust, Patient, Cancer, Precision medicine, Health, Hepatitis, Inflammation, AIH, Physician, CT1, Disease management, MRI, Disease, Medical imaging

Patients with AIH often experience recurring periods of subdued disease activity, experiencing few or no symptoms, followed by disease flares and worsening liver health making disease management exceptionally challenging for clinicians.

Key Points: 
  • Patients with AIH often experience recurring periods of subdued disease activity, experiencing few or no symptoms, followed by disease flares and worsening liver health making disease management exceptionally challenging for clinicians.
  • Clinical monitoring of AIH currently relies on blood biomarkers, which are non-specific and cannot detect small, but clinically relevant, changes in disease activity.
  • As the majority of patients with AIH require life-long monitoring, LiverMultiScan can help clinicians identify those with active sub-clinical disease, despite having normal blood markers, to provide tailored clinical treatment.
  • LiverMultiScan positively impacted physicians decision making with clinicians reporting high confidence in its utility in clinical management of patients with autoimmune hepatitis.

The Kypros Nicolaides Fetal Medicine And Therapy Center Opened At Abu Dhabi's Burjeel Medical City

Retrieved on: 
Tuesday, March 22, 2022
Rehabilitation, ABU, Medicine, Adult, Association, Pre-eclampsia, King's College Hospital, Pregnancy, Research, Macarius, Consultant, Medical director, VPS Healthcare, Birth certificate, Travel, Gestational diabetes, Hope, BMC, Southend University Hospital, Grand Cross, Maternal–fetal medicine, King, Patient, Mother, Hospital, Medical imaging

ABU DHABI, UAE, March 22, 2022 /PRNewswire/ -- A new fetal medicine and therapy center has been opened at Burjeel Medical City (BMC) in association with the world-renowned fetal medicine expert Prof. Kypros Nicolaides. Famously known as the 'Father of Fetal Medicine,' he is a Professor in the Fetal Medicine Research Institute at King's College Hospital, London. The Kypros Nicolaides Fetal Medicine and Therapy Center was inaugurated during a special ceremony at Burjeel Medical City, the largest medical care facility under the banner of VPS Healthcare, located in Mohammed Bin Zayed City, Abu Dhabi. The center is part of a collaboration between Prof. Kypros and the hospital's Fetal Medicine Department. 

Key Points: 
  • The center is part of a collaboration between the renowned Prof. Kypros Nicolaides and the hospital's fetal medicine department
    ABU DHABI, UAE, March 22, 2022 /PRNewswire/ -- A new fetal medicine and therapy center has been opened at Burjeel Medical City (BMC) in association with the world-renowned fetal medicine expert Prof. Kypros Nicolaides.
  • Famously known as the 'Father of Fetal Medicine,' he is a Professor in the Fetal Medicine Research Institute at King's College Hospital, London.
  • The Kypros Nicolaides Fetal Medicine and Therapy Centerwas inaugurated during a special ceremony at Burjeel Medical City,the largest medical care facility under the banner of VPS Healthcare, located in Mohammed Bin Zayed City, Abu Dhabi.
  • Dr. Mandeep Singh, Former Director of the Kypros Nicolaides Fetal Medicine Center at Southend University Hospital NHS Foundation Trust, UK, will lead the medical team at the new center as the Medical Director and Consultant in Maternal & Fetal Medicine of Burjeel Farha.

The Kypros Nicolaides Fetal Medicine And Therapy Center Opened At Abu Dhabi's Burjeel Medical City

Retrieved on: 
Tuesday, March 22, 2022
Rehabilitation, ABU, Medicine, Adult, Association, Pre-eclampsia, King's College Hospital, Pregnancy, Research, Macarius, Consultant, Medical director, VPS Healthcare, Birth certificate, Travel, Gestational diabetes, Hope, BMC, Southend University Hospital, Grand Cross, Maternal–fetal medicine, King, Patient, Mother, Hospital, Medical imaging

ABU DHABI, UAE, March 22, 2022 /PRNewswire/ -- A new fetal medicine and therapy center has been opened at Burjeel Medical City (BMC) in association with the world-renowned fetal medicine expert Prof. Kypros Nicolaides. Famously known as the 'Father of Fetal Medicine,' he is a Professor in the Fetal Medicine Research Institute at King's College Hospital, London. The Kypros Nicolaides Fetal Medicine and Therapy Center was inaugurated during a special ceremony at Burjeel Medical City, the largest medical care facility under the banner of VPS Healthcare, located in Mohammed Bin Zayed City, Abu Dhabi. The center is part of a collaboration between Prof. Kypros and the hospital's Fetal Medicine Department. 

Key Points: 
  • The center is part of a collaboration between the renowned Prof. Kypros Nicolaides and the hospital's fetal medicine department
    ABU DHABI, UAE, March 22, 2022 /PRNewswire/ -- A new fetal medicine and therapy center has been opened at Burjeel Medical City (BMC) in association with the world-renowned fetal medicine expert Prof. Kypros Nicolaides.
  • Famously known as the 'Father of Fetal Medicine,' he is a Professor in the Fetal Medicine Research Institute at King's College Hospital, London.
  • The Kypros Nicolaides Fetal Medicine and Therapy Centerwas inaugurated during a special ceremony at Burjeel Medical City,the largest medical care facility under the banner of VPS Healthcare, located in Mohammed Bin Zayed City, Abu Dhabi.
  • Dr. Mandeep Singh, Former Director of the Kypros Nicolaides Fetal Medicine Center at Southend University Hospital NHS Foundation Trust, UK, will lead the medical team at the new center as the Medical Director and Consultant in Maternal & Fetal Medicine of Burjeel Farha.

Bionano Genomics Announces UK Footprint Expansion with Adoption of its Saphyr® System for Optical Genome Mapping in Two Genetic Laboratory Hubs within the United Kingdom’s National Health Service

Retrieved on: 
Wednesday, February 2, 2022
OGM, Standard of care, Private Securities Litigation Reform Act, Forward-looking statement, Child, Patient, Royal College of Pathologists, Software, Automation, SAN, Genomics, Chromosome, Central, GLH, Research, Technology, King's College Hospital, NHS, Adoption, COVID-19, Efficiency, Laboratory, Lymphatic system, Partnership, Medicine, National Health Service, Autism, United, Annual report, Company, Genome, GLOBE, Doctor of Philosophy, Security (finance), Biology, Lineagen, Genetics, Solution, Hospital, Pharmaceutical industry, Belfast City Hospital

These adoptions significantly increase the footprint for OGM in the UK, complementing previous Saphyr placements in Belfast City Hospital in Belfast, Northern Ireland and Kings College Hospital in London, England.

Key Points: 
  • These adoptions significantly increase the footprint for OGM in the UK, complementing previous Saphyr placements in Belfast City Hospital in Belfast, Northern Ireland and Kings College Hospital in London, England.
  • Both labs intend to evaluate the potential of OGM to detect chromosomal aberrations in hematologic malignancies, genetic conditions and specific solid tumors.
  • Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services, and software.